ArticleCardiovascular drugs and therapy2026
Dapagliflozin Inhibits Thrombin Induced ADAM17 Phosphorylation and Downstream ERK/p-c-Jun-mediated CTGF Induction to Prevent Neointimal Hyperplasia.
Article in Cardiovascular drugs and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeVascular restenosis following angioplasty remains a major clinical challenge driven by excessive vascular smooth muscle cell (VSMC) migration, proliferation, and fibrosis. Thrombin, a potent signaling molecule beyond its coagulative function, promotes neointimal hyperplasia. Dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been shown to exert cardiovascular protection independent of its glucose-lowering effects, yet its role in thrombin-mediated fibrotic signaling remains unclear.
methodsCultured A10 vascular smooth muscle cells were used to evaluate thrombin- stimulated A Disintegrin And Metalloprotease 17 (ADAM17), ERK1/2, c-Jun, and connective tissue growth factor (CTGF) by immunoblotting and migration analyses. Enzymatic activity (ADAM17 and thrombin) assays were tested by cell-free system kit. Pharmacological inhibition of ADAM17 by TAPI-1 and extracellular signal-regulated kinase (ERK) by U0126 were employed to delineate pathway hierarchy. An in vivo rat carotid artery balloon injury model was used to assess the effects of dapagliflozin on neointimal formation.
resultsThrombin stimulation markedly increased ADAM17 phosphorylation, ERK1/2 and c-Jun activation, and CTGF expression in A10 cells. Dapagliflozin significantly suppressed these responses in a concentration-dependent manner without affecting thrombin enzymatic activity. Inhibition of ADAM17 recapitulated the effects of dapagliflozin, confirming ADAM17 as a key upstream mediator of thrombin-induced ERK/c-Jun/CTGF signaling. Functionally, dapagliflozin attenuated VSMC migration in vitro and significantly reduced neointimal hyperplasia in the rat carotid artery balloon injury model.
conclusionDapagliflozin inhibits thrombin-induced ADAM17 activation and downstream ERK1/2-c-Jun-CTGF signaling, thereby limiting VSMC migration and neointimal formation after vascular injury. This SGLT2-independent mechanism provides new insight into the pleiotropic vasculoprotective actions of dapagliflozin and identifies ADAM17 as a potential therapeutic target for preventing vascular restenosis and fibrosis-related cardiovascular disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.